Cipla-Azithromycin

There is no image.

Azithromycin

Method of action: Bactericidal, Ophthalmologicals

Treatment option: Lyme Disease, Bronchitis, Community Acquired Pneumonia, Impetigo, Infection, Infection,Soft Tissue, Middle Ear Infection, COPD,Acute, Pneumonia, Sinus Infection

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cipla-Azithromycin

Cipla-Azithromycin is a prescription-only medicine containing the active component Azithromycin. It is categorized as a broad-spectrum antibiotic used to manage bacterial infections. This medication is a semi-synthetic derivative of Erythromycin characterized by its ability to inhibit bacterial growth, making it a foundational agent in antimicrobial therapy.

Quick Facts
Active Ingredient	Azithromycin (as dihydrate)
Form	Oral Tablet and Suspension
Pharmacological Class	Antibiotic (Macrolide / Azalide)
Common Use	Halting the growth of bacterial infections
Origin	Semi-synthetic (Erythromycin derivative)

What Type of Medicine is Cipla-Azithromycin? (Identity and Class)

Cipla-Azithromycin is identified by its active ingredient Azithromycin, which is a single-ingredient product classified as a macrolide antibiotic, specifically belonging to the azalide subgroup. Azithromycin possesses a specific chemical structure that provides stability at low pH and allows for extensive tissue penetration. This allows the medication to reach higher concentrations at the site of infection compared to the levels found in the bloodstream, facilitating delivery to the affected area.

Composition, Origin, and Available Forms (Composition and Form)

The active component, typically formulated as Azithromycin dihydrate, is a semi-synthetic compound structurally related to the macrolide Erythromycin. This chemical structure results in a longer half-life, a characteristic that often allows for shorter treatment durations. Cipla-Azithromycin is primarily available in two dosage forms for oral administration: solid tablets and a powder for reconstitution into an oral suspension (liquid). The liquid version is intended for patients who have difficulty swallowing solid tablets.

General Purpose of Azithromycin (Purpose and Benefit)

The primary purpose of Azithromycin is to act as a bacteriostatic agent that halts the progression of bacterial infections by interfering with bacterial protein synthesis. It functions by binding to the bacterial 50S ribosomal subunit, which prevents the growth of the peptide chain and stops pathogens from growing and reproducing. By suppressing bacterial multiplication, Azithromycin limits the spread of the pathogen, which assists the body's immune system in clearing the infection.

Regulatory References

What side effects are possible with Cipla-Azithromycin?

Possible Side Effects and Safety Information

Cipla-Azithromycin's safety profile is characterized by common gastrointestinal disturbances and several rare, but serious, systemic risks, as documented in regulatory information. Adverse reactions are generally categorized by frequency and system-organ class.

Adverse Reaction Scope

The most frequently reported adverse reactions are Gastrointestinal (Common: ge 1/100 to < 1/10), including diarrhea, nausea, abdominal pain, and vomiting.

Serious Adverse Reactions (Rare) documented in regulatory sources include:

Cardiovascular Events: Prolongation of the QT interval which may lead to a fatal arrhythmia, Torsades de Pointes. An increased short-term risk of acute cardiovascular death has been reported.
Hepatotoxicity: Severe, sometimes fatal, hepatic failure including fulminant hepatitis and hepatic necrosis.
Hypersensitivity: Severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Gastrointestinal: Clostridioides difficile-associated diarrhea (CDAD).

Safety-Related Restrictions and Considerations

The drug is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or with a history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use.

Population-Specific Safety: Caution is advised in patients with pre-existing QT prolongation, uncorrected electrolyte imbalances, or severe hepatic or renal impairment. Neonates (up to 42 days of life) treated with azithromycin carry a risk of developing Infantile Hypertrophic Pyloric Stenosis (IHPS). The long tissue half-life may lead to the reappearance of allergic symptoms after cessation of symptomatic therapy.

Overdose and Emergency Response

Cipla-Azithromycin Overdose and When to Seek Help

Overdosage with Cipla-Azithromycin has been documented in regulatory sources, with manifestations often reported as similar to the known adverse reactions. The clinical presentation typically involves the gastrointestinal system, presenting with symptoms such as severe nausea, vomiting, and diarrhea. Abdominal pain is also among the expected manifestations associated with exposure to high doses.

A critical concern noted in regulatory warnings is the risk to the cardiac system, particularly the potential for Prolongation of the QT interval. This physiological abnormality can escalate to a life-threatening, irregular heart rhythm known as Torsades de pointes (TdP). This risk underscores the requirement for urgent clinical assessment.

In the event of overdosage, the official regulatory instruction is to implement general symptomatic and supportive measures as required by the patient’s clinical status. No specific antidote is known for Azithromycin overdosage, making clinical monitoring and support the standard management protocol.

It is formally required to seek immediate medical attention if any symptoms of severe cardiac concern occur, including irregular heartbeat, shortness of breath, dizziness, or fainting. These conditions mandate professional medical assessment and observation due to the potential for fatal cardiac arrhythmias.

Therapeutic Uses of Cipla-Azithromycin

What Cipla-Azithromycin Treats: Main Uses and Benefits

Cipla-Azithromycin is used to help manage and relieve symptoms related to physical discomfort caused by specific bacterial infections across several key bodily systems. The medication generally provides supportive therapeutic benefit by addressing the underlying pathogens responsible for symptoms associated with acute or episodic changes. It is indicated for infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.

The drug is commonly used across conditions presenting with acute episodes, including pneumonia, bronchitis, tonsillitis/pharyngitis, sinusitis, and otitis media. It is also relevant for managing uncomplicated skin infections and certain Sexually Transmitted Infections (STIs). Furthermore, in clinical settings, it may be part of symptomatic management for conditions where symptoms may intensify temporarily, such as COPD or non-cystic fibrosis bronchiectasis.

“It helps address symptom clusters that may become intense or disruptive, supporting patients during difficult episodes.”

Quick Fact: Relief for Acute Symptoms

Feature	Therapeutic Focus
Primary Domain	Acute Respiratory Infections (LRT/ENT)
Symptom Easing	Persistent cough, sore throat, earache, fever
Patient Benefit	Contributes to improved comfort during symptomatic periods
Specialized Use	Symptomatic management of acute exacerbations in chronic lung disease

Regulatory References

Azithromycin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Cipla-Azithromycin (Azithromycin) is subject to specific regulatory eligibility rules that define its permitted and prohibited use across different population groups.

Who Cannot Use Azithromycin?

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Azithromycin, Erythromycin, or any macrolide or ketolide antibiotic. Use is also prohibited for patients with a history of cholestatic jaundice or hepatic dysfunction previously associated with Azithromycin.

Age-Based and Conditional Eligibility

Population Group	Eligibility Status
Infants (< 6 months)	Not established (Safety and effectiveness are not established for most indications.)
Children (≥ 6 months)	Permitted (Established for specific indications like Acute Otitis Media.)
Older Adults	Permitted (Use is established; no age-based dosage adjustment is required.)

Use is not recommended for patients with severe hepatic impairment, as the drug is principally eliminated via the liver. Special caution is required for patients with severe renal impairment (GFR < 10 mL/min), as well as those with pre-existing proarrhythmic conditions like known QT prolongation or Myasthenia Gravis, due to the potential for exacerbation. For pregnant women, use is permitted only if clearly needed, and caution is advised for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define specific interaction patterns for Azithromycin (Cipla-Azithromycin) that structure its co-administration constraints. These interactions are classified based on their effect on drug exposure, cardiac function, and absorption.

Official Interaction Statements

Category	Interacting Substance	Official Constraint or Outcome
Contraindicated	Ergot Derivatives (e.g., Ergotamine)	Co-administration is formally prohibited due to the theoretical risk of ergotism.
Pharmacodynamic	QT-Prolonging Drugs	May lead to an additive effect on the QT interval, increasing the risk of arrhythmias.
Pharmacodynamic	Warfarin and Oral Anticoagulants	May potentiate the anticoagulant effect, requiring careful monitoring of Prothrombin Time/INR.
Pharmacokinetic	Nelfinavir (HIV Protease Inhibitor)	A PK interaction that significantly increases Azithromycin's Cmax and AUC, necessitating monitoring for adverse reactions.
Transporter	Digoxin (P-gp substrate)	Azithromycin is a P-glycoprotein inhibitor, which may lead to increased Digoxin serum concentrations.

Administration Timing Rule

Co-administration with Aluminum or Magnesium Hydroxide Antacids reduces Azithromycin's peak plasma concentration ( C max) by approximately 24%. To manage this absorption interference, regulatory labeling requires that antacids be administered at least 2 hours apart from Azithromycin.

The overall interaction profile requires close monitoring for coagulation changes and cardiac effects, alongside adherence to mandatory timing rules for co-administered products that affect gastrointestinal absorption.

Mechanism of Action

Cipla-Azithromycin (Azithromycin) functions as a bacteriostatic inhibitor with auxiliary immunomodulatory properties. Its primary target is the bacterial 50S ribosomal subunit, where it binds reversibly to the 23S rRNA component at the entrance of the nascent peptide exit tunnel. This interaction physically obstructs the tunnel, arresting the elongation and translocation of the polypeptide chain. This molecular cascade suppresses the fundamental protein synthesis pathway required for bacterial growth and replication. Beyond this antimicrobial action, Azithromycin also modulates the host's inflammatory cascade by reducing the output of specific pro-inflammatory cytokines (e.g., IL-6, IL-8). The molecule is actively concentrated by phagocytic cells (macrophages and neutrophils), which acts as a physiological transport mechanism to deliver the drug to inflamed tissues. The mechanism is constrained by bacterial ribosomal methylation or efflux pumps that block binding or actively expel the molecule, resulting in a loss of bacteriostatic effect.

Dosage and Administration Information

How to Use Cipla-Azithromycin

Azithromycin usage is defined by specific administration routes, fixed-duration regimens, and standardized frequency. The medicine is administered primarily via the oral route as tablets or suspension, and secondarily as an intravenous (IV) infusion for initial therapy in specific severe infections. Treatment often begins with the IV route, transitioning to oral administration to complete a full course.

Dosing Regimens and Frequency

The general principle of use is once daily administration across various courses. Most standard adult regimens involve a total cumulative dose of 1,500 mg delivered over either a 3-day course (500 mg once daily) or a 5-day course (500 mg on Day 1, then 250 mg on Days 2–5). Certain infections are treated with a single oral dose of 1,000 mg. Pediatric dosing is determined by body weight (mg/kg) using these same short-course patterns.

Administration Conditions

Oral tablets and suspension may be taken with or without food. A specific timing constraint requires separating the oral dose from antacids containing aluminum or magnesium by at least 1 hour before or 2 hours after administration. The intravenous form must be prepared and delivered as a slow infusion over 60 minutes or longer; it is constrained from being given as a rapid bolus or intramuscular injection.

These standardized instructions define the approach for administering the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has explored whether the intervention was associated with changes in patient outcomes related to pain. These trials, often involving several hundred participants, primarily examined the intervention's activity and safety profile over a six-month period.

Primary Endpoint Analysis: Studies examined the percentage change in the Visual Analog Scale (VAS) score from baseline. Findings were mixed regarding superiority over placebo, with some cohorts showing a statistically significant difference while others did not.
Safety Profile: The most frequently observed adverse events included gastrointestinal upset and headache. Research has evaluated the tolerability of this treatment, including in cohorts with mild cardiovascular issues.
Long-Term Follow-up: Observed changes in symptom severity were evaluated in long-term care settings. Follow-up studies extending up to 12 months were designed to examine durability and sustained safety.

Mechanism of Action (Pre-clinical and Phase I/II)

Research evaluated the intervention's effect on COX-2 pathways, and research evaluated changes in acute pain episodes. Pre-clinical research involved observations related to reduced markers of inflammation.

Cytokine Modulation: One study highlighted the drug’s evaluated effect against chronic inflammation, in which findings were recorded in relation to changes in markers related to disease progression. This area requires further investigation through randomized controlled trials.
Pharmacokinetics: Studies have evaluated whether taking the medication with food affects observed outcomes. The medication's absorption and half-life were evaluated across different patient demographics.

Emerging Research in Combination Therapies

Research has begun to examine the use of this intervention in conjunction with traditional disease-modifying agents. Combined therapy was evaluated for potential additive effects, and studies examined the overall prognosis. Evidence in this area remains limited, primarily consisting of small pilot studies.

Focus on Rheumatoid Conditions: Several small studies evaluated whether the combination affected joint swelling and C-reactive protein (CRP) levels in patients with rheumatoid arthritis. Results have not demonstrated a synergistic outcome.
Next Steps: Future large-scale, randomized controlled trials (RCTs) are needed to further evaluate the comparative effectiveness and safety of combined versus monotherapy.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cipla-Azithromycin (FAQ)

Q: What is the half-life of Azithromycin?

Official prescribing information indicates that Azithromycin has a long elimination half-life, which is the time required for half of the drug to be eliminated from the plasma. The average terminal half-life is approximately 68 hours. This prolonged duration is consistent with the drug’s characteristic of being actively taken up by tissues and then released slowly over time.

Q: Can I take this medication with or without food?

According to the official product information, Azithromycin oral tablets or oral suspension can be taken with or without food. This means the oral forms can be taken regardless of whether you have eaten or not. However, it is essential to remember that specific timing constraints apply if you are also taking certain antacids containing aluminum or magnesium.

Q: What should I do if I miss a dose?

Regulatory documents state that if a dose is missed, it should be taken as soon as remembered. If it is close to the time for the next scheduled dose, the label advises skipping the missed dose and returning to the regular dosing schedule. It is explicitly noted that a dose should not be doubled to make up for the missed one.

Q: Is this drug effective against fungal infections?

Azithromycin is classified as an antibiotic and its primary use is to halt the growth of bacterial infections. The official safety information notes that observation for signs of superinfection with non-susceptible organisms, which includes fungi, is recommended. This is a common precaution when taking an antimicrobial agent.

Q: How long does Azithromycin stay in your system after the last dose?

Studies show that Azithromycin has an extended terminal elimination half-life of approximately 68 hours. This prolonged presence is due to the drug being actively absorbed by cells in the body's tissues and then slowly released over time. This tissue concentration is why the drug can remain in the body longer than many other medicines.

Q: Can I drive a car while taking Cipla-Azithromycin?

Official product information notes that Azithromycin may cause side effects such as dizziness or visual impairment in some people. Due to this potential for impairment, caution is generally advised regarding driving or operating machinery until a person knows how the medication affects them.

How should Cipla-Azithromycin be stored and disposed of?

Storage and Disposal of Cipla-Azithromycin

The storage of Azithromycin is defined by its formulation and stability requirements, as mandated in official regulatory labeling.

Official Storage Requirements

Condition	Requirement	Form Applicable
Temperature	Store tablets at controlled room temperature (20 C to 25 C). Dry powder must be stored below 30 C.	Tablets, Dry Powder
Protection	Keep all forms out of the reach of children. Dry powder must be protected from light.	All Forms
Container	Must be stored in the original container to maintain integrity.	Tablets

Stability and Handling

The multi-dose oral suspension, once mixed, must be stored at or below 30 C and is stable for 10 days; it must not be frozen. The single-dose suspension must be used within 12 hours of mixing and not refrigerated.

Disposal Mandates

Disposal of any unused product or waste material must be conducted in accordance with local regulatory requirements. Any remaining single-dose liquid suspension must be discarded after use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

South Africa

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z